2012;12(1):65-74. The NE is composed of three morphologically ... IIF: Immunofluorescence; PBC: Primary biliary cirrhosis.

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

This study analyzes the link between these drugs and biliary adverse events (AEs) using the FDA Adverse Event Reporting System (FAERS) to enhance clinical safety. Methods: We extracted AE data for GLP ...

The study period was from 1 January 2010 to 31 December 2020 ... HCV/HDV/HEV co-infection, alcoholic cirrhosis, biliary cirrhosis, history of cirrhosis-related complications, and chronic kidney ...

Glucagon-like peptide 1 receptor agonists (GLP-1RAs ... or other causes of cirrhosis (eg, biliary, infectious, or childhood cirrhosis) were excluded. As experience with these novel ...

Resmetirom significantly reduced liver stiffness in patients with compensated MASH cirrhosis, with a 6.7 kPa decrease over 2 years. The reduction in liver stiffness may lower the risk of liver ...

Cirrhosis of the liver poses a significant health challenge worldwide. With no known cure, it requires comprehensive management to slow liver damage, alleviate symptoms and prevent potential ...

nonsurgical management among patients with obesity and compensated cirrhosis from metabolic dysfunction-associated steatohepatitis, according to study data. Permanent life insurance shares notable ...

Gallbladder cancer, a highly aggressive disease, often goes undiagnosed until advanced stages due to nonspecific symptoms and lack of routine screening. Risk factors include chronic inflammation, ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).